AstraZeneca said it had successfully completed its acquisition of California-based biotechnology company Ardea Biosciences.
The pharmaceutical giant said the $1.2bn deal would strengthen its late-stage pipeline with the addition of lesinurad, which is aimed at patients with gout.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
At the time the deal completed the prices had equalised with Ardea shares changing hands at $31.96 at the close on Tuesday.
With the takeover complete, each outstanding share of Ardea common stock has been cancelled and converted into the right to receive $32.00, in cash, without interest.
Shares of Ardea have ceased trading on the NASDAQ.
-
Nationwide Building Society launches £175 switching deal – who is eligible?Nationwide Building Society has launched a new current account switching deal. We look at whether you are eligible, and how to get the free cash.
-
Barclays launches £500 cashback offer for ISAs - but there's a catch. Here's how it worksBarclays is looking to attract savers to its cash ISA range but you need a lot of money to get the full reward
